High-Dose Thyroid Hormone As a Mood Stabilizer
in Bipolar Disorder
(Written 10/2007; updated 2012)
This webpage describes the use of thyroid hormone as a treatment for rapid cycling bipolar disorder. If you did not arrive from my main page on Thyroid Hormone and Bipolar Disorder, you could start there for some basics about this hormone and why it is relevant for this illness.
To summarize the information below: several independent research groups have been studying this treatment approach. The results are not conclusive, primarily because we need several more studies to confirm the initial results. Only one so far is a "randomized trial" comparing results versus a placebo treatment -- and the data have not been published yet. But the results so far are quite promising, and the risk levels appear to be very low, so this approach is worth at least knowing about. For patients who have tried many other approaches, this represents one more alternative. Because the risks appear to be so low, it might even be worth considering early in the usual progression through standard mood stabilizer medication options. More data on its effectiveness would be nice, of course.
This high-dose approach has been described by a research group which has done most of the investigations, in a review article which provides a nifty summary if you are trying to get references to your doctors. Because otherwise your job will be quite difficult in this respect, I have taken the liberty of giving you a direct link to this document, which follows my summary below. All errors in interpretation are my responsibility. (If anyone objects to my having made this paper available in this fashion, please let me know and I will remove the link.)
Until recently, the only evidence for use of high-dose thyroid as a treatment for mood problems consisted of case reports and small case series. No randomized trial versus a placebo was available, which is the most important evidence to establish that a treatment really does produce benefits. Now such a trial has been conducted, and some of the results were shared at a recent meeting* (not published yet).
Although caution is still warranted, because these results have not been subjected to critical examination, the pending arrival of these randomized data is a major event. We desperately need a mood stabilizer treatment that does not cause weight gain or other major risks; and that is inexpensive. Usually it is best to wait for several different research studies, all arriving at the same conclusion, before getting too excited about a new treatment. But the high-dose approach is so simple, so inexpensive, and perhaps even very low in risk (although like any other treatment, that will take years to really establish), it may now be worth considering among the ranks of the standard "mood stabilizer" treatments.
In an October bipolar meeting in Barcelona (2006), researchers from Berlin presented information on their randomized trial using 300 mcg of thyroid hormone. Unlike the information we have been working from previously, this was a large study. It is not complete yet. At that point they were still taking the last few subjects into the trial. However, it was noted that many patients in the trial improved very substantially. After the randomized phase, patients who wished to do so were allowed to continue on high-dose thyroid. In six-month follow-up, "most patients showed further improvement". Therefore, for the moment, in an admittedly very hopeful way, I am taking this conference report* as preliminary evidence that the randomized trial will show benefit greater than placebo.
When that weight of evidence is added to the previous open-trial data, it creates a relatively compelling case for this treatment approach. At that point, it becomes rational to consider the relative risks, compared to other "mood stabilizer" treatments.
*Randomized trial versus placebo, in Berlin; described in a news release (see the right-hand, third column; the article about Dr. Stamm's presentation)
Who might benefit?
Most of the open-trial data on this treatment approach has focused on patients with rapid cycling bipolar disorder. As best I can tell, the Berlin randomized trial described above may have focused on bipolar depression. "Treatment-resistant" depression, whether bipolar or unipolar (a very difficult distinction in this group of patients), may also respond to this approach.
What are the risks, and side effects?
Surprisingly, this approach is generally tolerated very well. You would think that people would become hyperthyroid, which would lead to the following symptoms:
But that does not seem to happen for patients who do well with this approach. Pulse rates to go up, generally about 10-20 beats per minute. Some minor symptoms from the above list were noted by some patients, but not to the point of requiring a treatment change. The researchers note that in patients who do not have bipolar disorder, high-dose thyroid would be expected to produce substantial levels of these symptoms.
Becoming hyperthyroid on your own, because your thyroid gland is not working properly, has been associated with an increased frequency of an abnormal heart rhythm called "atrial fibrillation". This is not lethal, but it is uncomfortable. Heart pumping capacity decreases by about half, and people feel quite strange. They often go to the emergency room, where generally this abnormal rhythm can be corrected.
But does taking thyroid hormone cause this same increased frequency of atrial fibrillation? in other words, does it make a difference, when the thyroid hormone comes into your body from the outside, instead of when you make it (due to a hyperthyroid state) from the inside? This is not known. All we can say at this point is that in following the patients who are using this high-dose thyroid approach, the researchers have not seen episodes of atrial fibrillation. Of course, at this point they may not have seen enough patients to catch the few cases which might arise from this treatment, so we cannot yet say that thyroid hormone from the outside is different in this respect.
UPDATE 2011: as you may have seen on my Thyroid and Bipolar page, we have new data on this issue. In case you haven't seen it, I'll copy it for you here, because it has such an impact on evaluating the risk of this treatment;
Risk #2, Bone: This only applies if you stay on high doses of thyroid treatment, presumably because you and your doctor have decided that the treatment is working really well. If you try the treatment and conclude in a month or two that it is not working, this risk is not an issue. The risk that has been associated with staying hyperthyroid due to an overactive thyroid gland is osteoporosis -- loss of calcium in your bones, with a risk of fractures, especially when you get older.
But so far, In a 5-year follow-up of patients being treated with high doses of thyroid hormone for bipolar disorder, this was not a problem. Bone density decreased, because the average age in this study was 50, and we all are going down at that age (so to speak; it's the voice of experience...). But there was no more bone loss than was seen in people of the same age and gender who were not being treated.Ricken
( Here finally is one place where being a heavy woman is an advantage: you're much less likely to have a problem with osteoporosis. But if you're fairly thin, or smoke, or your mother already has osteoporosis, you can't afford to add another factor that could cause bone thinning. Here's a little more on this topic for such women.)
For more information on this issue, see my collection of links on bone risk in thyroid treatment.
Update 2012: Hyperthyroid and "mixed states": a new case report Rao describes a patient who had agitation and depression at the same time, associated with being hyperthyroid (symptoms resolved when her own thyroid hormone production was lowered). This raises the possibility that in addition to inducing hyperthyroid symptoms, high doses of thyroid hormone could induce a "mixed state". Unfortunately, mixed states are relatively common in people with rapid cycling, the very ones who might theoretically benefit from the high-dose thyroid strategy. THEREFORE it now appears that one must keep in mind (a tiny bit more than one did before this case report) the possibility that if a person is on the high-dose approach and having "mixed state" symptoms, this could be from the thyroid dose. Remember, it's only a single case report and it was in a patient who was hyperthyroid on her own, not from high-dose thyroid treatment.
Tests to do before starting
Several groups of patients would not be suitable for this treatment approach, and so must be sought before treatment begins. These include:
The researchers also recommend some procedures which may require modification for use in the real world, as opposed to a research setting. For example, they recommend a measure of bone density (an expensive test) before treatment begins, whereas I think it makes more sense to limit this to women who have other reasons for concern about bone density, or at least those who do so well on the treatment that it will be continued long-term. An electrocardiogram is recommended for patients with a history of heart rhythm problems, and a consultation with an endocrinologist/internist for patients with a history of thyroid abnormalities.
Doses used for starting
(mcg per day)
(TSH in the normal range)
(TSH elevated, T4/T3 low)
*reach euthyroid status in 6-8 weeks
Lab tests during follow-up
In this high-dose approach, think about what will happen to TSH.
If you followed the story about TSH lab result interpretation, you
will understand that high dose thyroid treatment drives TSH down to very
low levels, zero or close to zero. When starting this treatment, everyone should be prepared to see
the TSH go that low. This should not be a surprise, and it should be accepted as part of the plan.
What about the other lab tests, like the T4 level, or T3 level? In the article linked below, the researchers with the most experience using this approach recommend allowing an increase in T4 up to 150% of the starting T4 level. In a personal communication, one of the researchers talked in terms of "150% of the upper limit of normal", which is obviously likely a little higher number. As for T3 (what is T3?), if we had our good reliable measure of this one hormone, especially one that was cheap, this might be the best marker of all, as it is closer to what might be the important physiological endpoint. The researchers point out that if this one is not elevated, perhaps the patient is not really hyperthyroid?
To summarize this issue: there is no accepted laboratory marker indicating the upper limit of this process if the patient him or herself does not have signs or symptoms of hyperthyroidism. This is still being worked out
in research. Obviously what matters is to prevent bad outcomes that might be associated with "too high a dose". But how can we say what it is too high, except based on bad outcomes or on some understanding of the physiology? (as you'll see below, not much of the relevant physiology is understood)
Think about it this way: if the patient does not have signs and symptoms of hyperthyroidism, but the laboratory studies are in the "hyperthyroid" range, who is correct -- the lab results, or the patient? It is such a person really "hyperthyroid"? Is she or he really at increased risk of atrial fibrillation and decreased bone density?
Remember, these risks were originally recognized in patients who were "naturally hyperthyroid": they were made hyperthyroid by their own gland, not by someone giving them thyroid hormone. We do not yet know if high-dose thyroid creates the same risks, presuming that the patient is not symptomatic. For now, I think we can summarize by saying that there is no consensus on how to judge how much thyroid hormone is too much. Going to 300 mcg, as used in the randomized trial in Berlin, seems a reasonable upper limit for now. In cases where many other approaches have been tried, going to 400 mcg or even a little higher seems justifiable. I personally will be using "T4 up to 150% of the upper limit of normal".
If this seems radical, or daring, or even "Western cowboy style" medicine, think about the kinds of risks to which we expose patients when we use a medication that has just been approved by the FDA. How shall we define the upper limits of acceptable treatment? What are the risks of going to that level, or beyond? how much risk are we taking just getting to levels that manufacture has already deemed acceptable? When a medication is new, these are almost completely unknown -- perhaps even more unknown than the risks of the thyroid approach discussed here.
How does this work?
Seems like a strange idea, using these high doses. Does anyone know how this ends up having a mood stabilizer effect? Basically, the answer is no. Remember, T3 is the active version of thyroid hormone. The researchers point out that when someone becomes spontaneously hyperthyroid, from their own thyroid gland overproduction, they have increased levels of T3 as well as T4. When T4 thyroid is given as a pill, from the outside, even at high doses, T3 levels are not abnormal. In this respect, the patient is not "hyperthyroid", at least in the same sense as if TSH went to zero from his or her own thyroid production. Thyroid hormone control is extremely complicated. Using high doses of thyroid is simply bumping a system we don't understand very well. Unfortunately, this is what similar to the situation we face using nearly any medication for bipolar disorder (although our understanding of the causes of bipolar disorder is improving rapidly).
How to Explain This to Your Doctors
Most primary care physicians and endocrinologists have never heard anything about this high-dose approach. But some physicians have been using thyroid hormone for patients with mood problems for years, without a clear rationale. In their opinion, it just seemed to work and not cause too much trouble. Because there was no research behind this approach, it was thought to be almost irresponsible, at least by some endocrinologists. Therefore, if you are considering high-dose thyroid, you are very likely to run into resistance to the idea from other doctors. You can send them to this webpage, if they will go, but for many doctors you might need to walk in with a review article from a source with very good credentials on this issue. Because you could not easily put your hand on this otherwise, and you are so likely to need it, I offer you a link below to a PDF you can print. (Again, if anyone objects to my having made this available, please let me know and I will take it down and post an explanation of the objection.)
The Article You Will Need to Take to Your Doctors